Feasibility of home-based exercise training during adjuvant treatment for metastatic castrate-resistant prostate cancer patients treated with an androgen receptor pathway inhibitor (EXACT)

被引:4
作者
Brown, Malcolm [1 ]
Murphy, Marie H. [2 ,3 ]
McAneney, Helen [4 ,5 ]
McBride, Ken [6 ]
Crawford, Ffiona [6 ]
Cole, Aidan [7 ,8 ]
O'Sullivan, Joe M. [7 ,8 ]
Jain, Suneil [7 ,8 ]
Prue, Gillian [1 ]
机构
[1] Queens Univ Belfast, Med Biol Ctr, Sch Nursing & Midwifery, 97 Lisburn Rd, Belfast BT9 7BL, North Ireland
[2] Ulster Univ, Ctr Exercise Med Phys Act & Hlth, Sch Sport, Belfast, North Ireland
[3] Univ Edinburgh, Sch Educ & Sport, Edinburgh, Scotland
[4] Ulster Univ, Sch Med, Northern Ireland Publ Hlth Res Network, Belfast, North Ireland
[5] Univ Coll Dublin, Sch Nursing Midwifery & Hlth Syst, Dublin, Ireland
[6] Northern Ireland Canc Res Consumer Forum, Belfast, North Ireland
[7] Belfast Hlth & Social Care Trust, Northern Ireland Canc Ctr, Belfast, North Ireland
[8] Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Belfast, North Ireland
关键词
Exercise; Feasibility; Metastatic prostate cancer; Functional fitness; Health-related quality of life; QUALITY-OF-LIFE; DEPRIVATION THERAPY; BODY-COMPOSITION; FUNCTIONAL ASSESSMENT; PHYSICAL-ACTIVITY; MEN; ENZALUTAMIDE; STRENGTH; MECHANISMS; COUNTRIES;
D O I
10.1007/s00520-023-07894-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundExercise is an effective adjuvant therapy that can alleviate treatment-related toxicities for men with prostate cancer (PC). However, the feasibility of delivering exercise training to men with advanced disease and the wider impact on clinical outcomes remain unknown. The purpose of the EXACT trial was to determine the feasibility and effects of home-based exercise training in men with metastatic castrate-resistant prostate cancer (mCRPC).MethodsPatients with mCRPC receiving ADT + an androgen receptor pathway inhibitor (ARPI) were prescribed 12 weeks of home-based, remotely monitored, moderate intensity, aerobic and resistance exercise. Feasibility was assessed using recruitment, retention and adherence rates. Safety and adverse events were monitored throughout, with functional and patient-reported outcomes captured at baseline, post-intervention and at 3-month follow-up.ResultsFrom the 117 screened, 49 were deemed eligible and approached, with 30 patients providing informed consent (61% recruitment rate). Of those who consented, 28 patients completed baseline assessments, with 24 patients completing the intervention and 22 completing follow-up (retention rates: 86% and 79% respectively). Task completion was excellent throughout, with no intervention-related adverse events recorded. Self-reported adherence to the overall intervention was 82%. Exercise training decreased mean body mass (-1.5%), improved functional fitness (> 10%) and improved several patient-reported outcomes including clinically meaningful changes in fatigue (p = 0.042), FACT-G (p = 0.054) and FACT-P (p = 0.083), all with moderate effect sizes.ConclusionHome-based exercise training, with weekly remote monitoring, was feasible and safe for men with mCRPC being treated with an ARPI. Given that treatment-related toxicities accumulate throughout the course of treatment, and as a result, negatively impact functional fitness and health-related quality of life (HRQoL), it was positive that exercise training improved or prevented a decline in these clinically important variables and could better equip patients for future treatment. Collectively, these preliminary feasibility findings support the need for a definitive, larger RCT, which downstream may lead to the inclusion of home-based exercise training as part of adjuvant care for mCRPC.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Feasibility of home-based exercise training during adjuvant treatment for metastatic castrate-resistant prostate cancer patients treated with an androgen receptor pathway inhibitor (EXACT)
    Malcolm Brown
    Marie H. Murphy
    Helen McAneney
    Ken McBride
    Ffiona Crawford
    Aidan Cole
    Joe M. O’Sullivan
    Suneil Jain
    Gillian Prue
    Supportive Care in Cancer, 2023, 31
  • [2] Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer
    Hanson, Erik D.
    Alzer, Mohamdod
    Carver, Jackson
    Stopforth, Cameron K.
    Lucas, Alexander R.
    Whang, Young E.
    Milowsky, Matthew, I
    Bartlett, David B.
    Harrison, Michael R.
    Bitting, Rhonda L.
    Deal, Allison M.
    Stoner, Lee
    Hackney, A. C.
    Battaglini, Claudio L.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2023, 26 (02) : 302 - 308
  • [3] Exercise for advanced prostate cancer: a multicomponent, feasibility, trial protocol for men with metastatic castrate-resistant prostate cancer (EXACT)
    Brown, Malcolm
    Murphy, Marie
    McDermott, Lauri
    McAneney, Helen
    O'Sullivan, Joe M.
    Jain, Suneil
    Prue, Gillian
    PILOT AND FEASIBILITY STUDIES, 2019, 5 (01)
  • [4] Exercise for advanced prostate cancer: a multicomponent, feasibility, trial protocol for men with metastatic castrate-resistant prostate cancer (EXACT)
    Malcolm Brown
    Marie Murphy
    Lauri McDermott
    Helen McAneney
    Joe M. O’Sullivan
    Suneil Jain
    Gillian Prue
    Pilot and Feasibility Studies, 5
  • [5] Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer
    Zsofia, Kueronya
    Krisztina, Biro
    Fruzsina, Gyergyay
    Lajos, Geczi
    ORVOSI HETILAP, 2017, 158 (02) : 42 - 49
  • [6] Patients' Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment
    Eliasson, Lina
    de Freitas, Hayley M.
    Dearden, Lindsay
    Calimlim, Brian
    Lloyd, Andrew J.
    CLINICAL THERAPEUTICS, 2017, 39 (04) : 723 - 737
  • [7] Updates in the Treatment of Non-Metastatic Castrate-Resistant Prostate Cancer: The Benefit of Second-Generation Androgen Receptor Antagonists
    Hadfield, Matthew J. J.
    Lyall, Vikram
    Holle, Lisa M. M.
    Dennison, Morgan
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (11) : 1302 - 1311
  • [8] Taxanes Versus Androgen Receptor Therapy as Second-Line Treatment for Castrate-Resistant Metastatic Prostate Cancer After First-Line Androgen Receptor Therapy
    Broyelle, Antonin
    Delanoy, Nicolas
    Bimbai, Andre-Michel
    Le Deley, Marie-Cecile
    Penel, Nicolas
    Villers, Arnauld
    Lebellec, Loic
    Oudard, Stephane
    CLINICAL GENITOURINARY CANCER, 2023, 21 (03) : 349 - +
  • [9] Patients' and partners' views of care and treatment provided for metastatic castrate-resistant prostate cancer in the UK
    Catt, Susan
    Matthews, Lucy
    May, Shirley
    Payne, Heather
    Mason, Malcolm
    Jenkins, Valerie
    EUROPEAN JOURNAL OF CANCER CARE, 2019, 28 (06)
  • [10] The “home-based exercise for breast and prostate cancer patients during treatment—a feasibility trial” (BENEFIT CA trial): rationale and methodological protocol
    Larissa Xavier Neves da Silva
    Jayne Santos Leite
    Andresa Conrado Ignacio
    Fernanda Dias Massierer
    Lucinéia Orsolin Pfeifer
    Linda Ariene dos Santos Cardoso
    Tainá Silveira Alano
    Daniel Umpierre
    Pilot and Feasibility Studies, 9